ASCO 2017 - ALL: 75% in phase 1/2 trial of KTE-C19 achieved MRD-CR

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • At a maximum tolerated dose of 2×106 CAR T cells/kg, 6 of 8 efficacy-evaluable patients achieved MRD-CR in this phase 1/2 trial of the anti-CD19 CAR T-cell therapy KTE-C19 (axicabtagene ciloleucel).

Why this matters

  • The autologous CAR T-cell therapy showed promise in relap...